ClearPoint Neuro (CLPT) Cash & Equivalents (2011 - 2026)

ClearPoint Neuro (CLPT) has 16 years of Cash & Equivalents data on file, last reported at $35.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 187.34% year-over-year to $35.6 million; the trailing twelve-month figure through Mar 2026 stood at $35.6 million (up 187.34% YoY), and the FY2025 full-year result was $45.9 million, up 128.47% from the prior year.
• Cash & Equivalents retreated to $35.6 million in Q1 2026, from $45.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $49.7 million in Q1 2022 to a low of $12.4 million in Q1 2025.
• A 5-year average of $29.3 million and a median of $26.5 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 67.54% in 2022 and surged 187.34% in 2026, its largest moves.
• Tracing CLPT's Cash & Equivalents over 5 years: stood at $27.6 million in 2022, then dropped by 16.35% to $23.1 million in 2023, then fell by 12.99% to $20.1 million in 2024, then soared by 128.47% to $45.9 million in 2025, then dropped by 22.49% to $35.6 million in 2026.
• Business Quant data shows CLPT's Cash & Equivalents at $35.6 million in Q1 2026, $45.9 million in Q4 2025, and $38.2 million in Q3 2025.